| Literature DB >> 34285764 |
Yasmeen Ahmed Salaheldin1,2, Salma Sayed Mohamed Mahmoud2,3, Ebenezeri Erasto Ngowi2,4, Vivian Aku Gbordzor2,5, Tao Li2,5, Dong-Dong Wu2,6, Xin-Ying Ji2,7.
Abstract
Various research works have piled up conflicting evidence questioning the effect of oxidative stress in cancer. Reactive oxygen and nitrogen species (RONS) are the reactive radicals and nonradical derivatives of oxygen and nitrogen. RONS can act as a double-edged weapon. On the one hand, RONS can promote cancer initiation through activating certain signal transduction pathways that direct proliferation, survival, and stress resistance. On the other hand, they can mitigate cancer progression via their resultant oxidative stress that causes many cancer cells to die, as some recent studies have proposed that high RONS levels can limit the survival of cancer cells during certain phases of cancer development. Similarly, eukaryotic translation initiation factors are key players in the process of cellular transformation and tumorigenesis. Dysregulation of such translation initiation factors in the form of overexpression, downregulation, or phosphorylation is associated with cancer cell's altering capability of survival, metastasis, and angiogenesis. Nonetheless, eIFs can affect tumor age-related features. Data shows that alternating the eukaryotic translation initiation apparatus can impact many downstream cellular signaling pathways that directly affect cancer development. Hence, researchers have been conducting various experiments towards a new trajectory to find novel therapeutic molecular targets to improve the efficacy of anticancer drugs as well as reduce their side effects, with a special focus on oxidative stress and initiation of translation to harness their effect in cancer development. An increasing body of scientific evidence recently links oxidative stress and translation initiation factors to cancer-related signaling pathways. Therefore, in this review, we present and summarize the recent findings in this field linking certain signaling pathways related to tumorigeneses such as MAPK and PI3K, with either RONS or eIFs.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34285764 PMCID: PMC8275427 DOI: 10.1155/2021/5522054
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1A schematic presentation of RONS levels in the cell and their impact, the reasonable amounts of RONS are a key player for activating protective signaling pathways whereas elevated RONS is considered lethal to most cellular functions and may lead to cancer development. RONS: reactive oxygen and nitrogen species; P53: tumor suppressor; JNK: Jun N-terminal kinase.
Figure 2A schematic illustration of RONS regulation within cancer cells depicting some of the mechanisms used to reduce the extreme accumulation of RONS to reach the optimum level for cellular performance and survival. Excessive accumulation of RONS enhances cell death notably via ASK1/JNK/P38 MAPK pathway activation. RONS: reactive oxygen and nitrogen species; NRF2: nuclear factor erythroid-derived 2-like 2; PGC-1α: peroxisome proliferator-activated receptor gamma coactivator one alpha; HIF-1: hypoxic inducible factor one.
Functions of different eIFs.
| Protein | Function | Refs. |
|---|---|---|
| eIF1 | mRNA screening and delivery of tRNA. | [ |
|
| ||
| eIF2 | Initiation codon recognition. | [ |
| eIF2b | Allows for the next initiation to occur (returns the released GDP to GTP). | |
|
| ||
| eIF3 | Recruiting translation factors and 40S ribosome subunits to the mRNA. | [ |
|
| ||
| eIF4F | Multisubunit complex: | [ |
| (i) eIF4E | CAP binding activity, a rate-limiting factor. | |
| (ii) eIF4G | Scaffolding protein and interaction partner for other factors. | |
| (iii) eIF4A | RNA helicase. | |
| (iv) eIF4B and eIF4H | mRNA secondary structure unwinding. | |
|
| ||
| eLF5 | Translation elongation and bond formation. | [ |
|
| ||
| eIF6 | Prevents 60S subunit association with 40S subunit in the absence of mRNA (antiassociation factor). | [ |
eIF: eukaryotic initiation factor; mRNA: messenger RNA; tRNA: tranfer RNA; GDP: glutamine dipeptide; GTP: glutamine tripeptide; CAP: catabolite activator protein.
Dysregulated eIFs in different types of cancer.
| Protein | Form of dysregulation | Resultant cancer | Refs. |
|---|---|---|---|
| eIF1 | Overexpression | HCC | [ |
| Mutation | Thyroid cancer | [ | |
|
| |||
| eIF2 alpha | Increased Phosphorylation | Oropharyngeal | [ |
| Overexpression | Gastrointestinal | [ | |
| NSCL | [ | ||
| Lymphoma | [ | ||
| Brain tumor | [ | ||
| Thyroid carcinoma | [ | ||
|
| |||
| eIF3A | Overexpression | Colorectal | [ |
|
| |||
| eIF3B | Esophageal | [ | |
|
| |||
| eIF3C | Glioma | [ | |
|
| |||
| eIF3D | Breast | [ | |
| Prostate | [ | ||
| Gastric | [ | ||
|
| |||
| eIF3H | HCC | [ | |
|
| |||
| eIF3I | Head and neck | [ | |
|
| |||
| eIF3M | Colorectal | [ | |
|
| |||
| eIF3E | Downregulation | Breast | [ |
|
| |||
| eIF3F | Pancreatic | [ | |
|
| |||
| eIF4E | Overexpression | Brain | [ |
| Endometrial | [ | ||
| Head and neck | [ | ||
| Bladder | [ | ||
| Cervical | [ | ||
| Prostate | [ | ||
| Colon | [ | ||
| Liver | [ | ||
| Lymphoma | [ | ||
| Esophagus | [ | ||
| Gastric | [ | ||
|
| |||
| eIF4G | Nasopharyngeal | [ | |
| Breast | [ | ||
| Squamous cell lung cancer | [ | ||
| Cervical cancer | [ | ||
| Melanoma | [ | ||
|
| |||
| eIF4A | Downregulation | Breast | [ |
| Lung | [ | ||
|
| |||
| eIF4B | Overexpression | B-cell lymphoma | [ |
|
| |||
| eIF4H | Lung | [ | |
|
| |||
| eIF5 | Overexpression | HCC | [ |
| Glioblastoma | [ | ||
| Lung | [ | ||
| Urinary bladder | [ | ||
| Ovarian | [ | ||
| Colorectal | [ | ||
|
| |||
| eIF6 | Overexpression | Leukemia | [ |
| Ovarian serous | [ | ||
HCC: hepatocellular carcinoma; NSCL: non-small-cell lung cancer.